Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
EDAP logo EDAP
Upturn stock ratingUpturn stock rating
EDAP logo

EDAP TMS SA (EDAP)

Upturn stock ratingUpturn stock rating
$1.35
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: EDAP (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

3 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $5.75

1 Year Target Price $5.75

Analysts Price Target For last 52 week
$5.75 Target price
52w Low $1.21
Current$1.35
52w High $4.4

Analysis of Past Performance

Type Stock
Historic Profit -27.62%
Avg. Invested days 20
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 50.48M USD
Price to earnings Ratio -
1Y Target Price 5.75
Price to earnings Ratio -
1Y Target Price 5.75
Volume (30-day avg) 3
Beta -0.09
52 Weeks Range 1.21 - 4.40
Updated Date 08/15/2025
52 Weeks Range 1.21 - 4.40
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.68

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -34.33%
Operating Margin (TTM) -44.22%

Management Effectiveness

Return on Assets (TTM) -16.54%
Return on Equity (TTM) -49.28%

Valuation

Trailing PE -
Forward PE 38.02
Enterprise Value 34378696
Price to Sales(TTM) 0.8
Enterprise Value 34378696
Price to Sales(TTM) 0.8
Enterprise Value to Revenue 0.47
Enterprise Value to EBITDA 1165.78
Shares Outstanding 37392100
Shares Floating 29010276
Shares Outstanding 37392100
Shares Floating 29010276
Percent Insiders -
Percent Institutions 40.19

ai summary icon Upturn AI SWOT

EDAP TMS SA

stock logo

Company Overview

overview logo History and Background

EDAP TMS SA was founded in 1979 in France. It initially focused on developing and marketing medical devices for urology. Significant milestones include the development of focused ultrasound technologies for non-invasive treatment of various conditions and its public listing.

business area logo Core Business Areas

  • High-Intensity Focused Ultrasound (HIFU): Develops, manufactures, and markets HIFU devices for the non-invasive ablation of tumors, primarily prostate cancer. Core products include the Focal One and Ablatherm HIFU systems.
  • Extracorporeal Shockwave Lithotripsy (ESWL): Develops, manufactures, and markets ESWL devices for the non-invasive treatment of kidney stones. Core product is the Sonolith i-sys.

leadership logo Leadership and Structure

The company is led by Marc Oczachowski, Chief Executive Officer. The organizational structure includes departments for R&D, manufacturing, sales, marketing, and regulatory affairs.

Top Products and Market Share

overview logo Key Offerings

  • Focal One: A HIFU system for precise and personalized prostate cancer ablation. The estimated market share within the HIFU prostate cancer treatment market is approximately 25%. Competitors include Profound Medical (PROF), Sonacare Medical, and Exact Imaging.
  • Ablatherm: A HIFU system used for prostate cancer ablation. While older than Focal One, it still holds a presence. Market share is declining relative to Focal One and competitor systems. Competitors are similar to Focal One: Profound Medical (PROF), Sonacare Medical.
  • Sonolith i-sys: An ESWL system for treating kidney stones. The ESWL market is mature. Competitors include Siemens Healthineers (SIEGY), Dornier MedTech, and Olympus (OCPNY).

Market Dynamics

industry overview logo Industry Overview

The market for minimally invasive surgical and therapeutic devices is growing, driven by patient preference, technological advancements, and an aging population. The prostate cancer treatment market, in particular, is experiencing innovation in imaging and ablation technologies.

Positioning

EDAP TMS SA is positioned as a leader in HIFU technology for prostate cancer treatment. Its competitive advantages include its established brand, technological expertise, and clinical data supporting the efficacy of its HIFU systems.

Total Addressable Market (TAM)

The global prostate cancer diagnostics and treatment market is expected to reach $13.7 billion by 2028. EDAP TMS SA is positioned to capture a portion of this TAM through its HIFU technology, focusing on non-invasive ablation.

Upturn SWOT Analysis

Strengths

  • Leading HIFU technology
  • Established brand reputation
  • Strong clinical data
  • Global distribution network

Weaknesses

  • Reliance on HIFU market
  • Limited product diversification
  • Geographic concentration in Europe
  • Smaller company size relative to competitors

Opportunities

  • Expanding HIFU applications
  • Entering new geographic markets
  • Developing partnerships with imaging companies
  • Acquiring complementary technologies

Threats

  • Competition from established medical device companies
  • Technological advancements in alternative therapies
  • Regulatory changes
  • Economic downturns

Competitors and Market Share

competitor logo Key Competitors

  • Profound Medical (PROF)
  • Siemens Healthineers (SIEGY)
  • Intuitive Surgical (ISRG)

Competitive Landscape

EDAP TMS SA competes with larger medical device companies. Its advantage lies in its specialized HIFU technology. Its disadvantages include its smaller size and limited product diversification.

Growth Trajectory and Initiatives

Historical Growth: EDAP TMS SA has experienced revenue growth in recent years, driven by increased adoption of HIFU technology. However, profitability has been inconsistent.

Future Projections: Analysts project continued revenue growth, driven by expanding HIFU applications and geographic expansion. Profitability is expected to improve with scale.

Recent Initiatives: Recent strategic initiatives include expanding sales and marketing efforts, investing in R&D, and pursuing regulatory approvals in new markets.

Summary

EDAP TMS SA is a company specializing in HIFU technology for prostate cancer treatment and ESWL for kidney stones. While being a leader in its niche market, it faces competition from larger players. Its strengths are its technology and brand, while weaknesses include limited diversification. Overall, the company has potential for growth, but needs to capitalize on the market opportunities to improve the bottom line.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC Filings (10-K, 10-Q)
  • Company Investor Relations
  • Market Research Reports
  • Analyst Reports

Disclaimers:

The data and analysis provided are for informational purposes only and should not be considered investment advice. Market share estimates are approximate. Financial data is based on publicly available information and may be subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About EDAP TMS SA

Exchange NASDAQ
Headquaters -
IPO Launch date 1997-07-31
CEO & Director Mr. Ryan Rhodes
Sector Healthcare
Industry Medical Distribution
Full time employees 310
Full time employees 310

EDAP TMS S.A., together with its subsidiaries, develops, manufactures, promotes, and distributes minimally-invasive medical devices for urology based upon proprietary ultrasound technology in Asia, France, the United States, and internationally. The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution segments. The HIFU segment develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. This segment also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL segment manufactures and markets lithotripter for the treatment of urinary tract stones; and provides disposables, replacement parts, and services for lithotripters. This segment also sells spare parts and disposables, such as electrodes. The Distribution segment markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. It markets and sells its products through its direct marketing and sales channels, as well as through third-party distributors and agents. The company serves academic, public, and private hospitals as well as urology clinics. EDAP TMS S.A. was incorporated in 1979 and is based in Vaulx-en-Velin, France.